Premium Nahrungsergänzungsmittel | artgerecht

undefined

Regular tips about health Regular tips about health

Things worth knowing about "PCSK9"

PCSK9 is an enzyme that regulates blood cholesterol levels. Inhibitors of this enzyme are used to treat elevated LDL cholesterol and reduce cardiovascular risk.

What is PCSK9?

PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is an enzyme produced mainly by the liver that plays a key role in regulating LDL cholesterol levels in the blood. It controls how many LDL receptors are available on liver cell surfaces to capture and remove LDL cholesterol (often referred to as "bad" cholesterol) from the bloodstream.

Mechanism of Action

Under normal circumstances, LDL receptors on liver cells bind LDL particles from the blood and transport them into the cell for breakdown. After this process, the receptors are typically recycled back to the cell surface to capture more LDL.

PCSK9 disrupts this recycling process: it binds to the LDL receptor and directs it toward degradation inside the cell rather than recycling. The result is a reduced number of LDL receptors on the cell surface, which means less LDL is cleared from the blood and LDL cholesterol levels rise.

Clinical Significance

Overactive PCSK9 leads to significantly elevated LDL levels and greatly increases the risk of cardiovascular diseases such as heart attack and stroke. Conversely, individuals with loss-of-function mutations in the PCSK9 gene naturally have lower LDL levels and a substantially reduced risk of heart disease.

Genetic Variants

Gain-of-function mutations: Result in excessively high PCSK9 activity and markedly elevated LDL cholesterol (familial hypercholesterolemia).
Loss-of-function mutations: Result in low PCSK9 activity, very low LDL levels, and significantly reduced cardiovascular risk.

PCSK9 Inhibitors as Therapy

Based on the understanding of the PCSK9 mechanism, specific inhibitors known as PCSK9 inhibitors have been developed. These agents block the binding of PCSK9 to the LDL receptor, allowing more LDL receptors to be recycled and remain on the cell surface. The result is a significant reduction in LDL cholesterol levels.

Approved PCSK9 Inhibitors

Evolocumab (Repatha®): A monoclonal antibody administered by subcutaneous injection.
Alirocumab (Praluent®): Also a monoclonal antibody administered by injection.
Inclisiran: A novel RNA-based agent (siRNA) that directly inhibits PCSK9 production in the liver.

Indications

PCSK9 inhibitors are used in patients with:

Familial hypercholesterolemia (genetically elevated cholesterol)
High cardiovascular risk who do not achieve adequate LDL reduction despite maximally tolerated statin therapy
Statin intolerance

Side Effects and Safety

PCSK9 inhibitors are generally well tolerated. The most common side effects include:

Injection site reactions (redness, pain, swelling)
Nasopharyngitis (common cold-like symptoms)
Flu-like symptoms

Serious adverse effects are rare. Long-term studies demonstrate good tolerability and a significant reduction in the risk of heart attacks and strokes.

References

Sabatine, M. S. et al. - Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 2017.
European Society of Cardiology (ESC) / European Atherosclerosis Society (EAS) Guidelines for the Management of Dyslipidaemias, 2019.
Ridker, P. M. et al. - Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 2017.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.